214 related articles for article (PubMed ID: 7878192)
1. Actions of the E2-isoprostane, 8-ISO-PGE2, on the platelet thromboxane/endoperoxide receptor in humans and rats: additional evidence for the existence of a unique isoprostane receptor.
Longmire AW; Roberts LJ; Morrow JD
Prostaglandins; 1994 Oct; 48(4):247-56. PubMed ID: 7878192
[TBL] [Abstract][Full Text] [Related]
2. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist.
Morrow JD; Minton TA; Roberts LJ
Prostaglandins; 1992 Aug; 44(2):155-63. PubMed ID: 1438879
[TBL] [Abstract][Full Text] [Related]
3. Agonist-induced phosphorylation of human platelet TXA2/PGH2 receptors.
Okwu AK; Mais DE; Halushka PV
Biochim Biophys Acta; 1994 Mar; 1221(1):83-8. PubMed ID: 8130280
[TBL] [Abstract][Full Text] [Related]
4. Vascular smooth muscle actions and receptor interactions of 8-iso-prostaglandin E2, an E2-isoprostane.
Fukunaga M; Takahashi K; Badr KF
Biochem Biophys Res Commun; 1993 Sep; 195(2):507-15. PubMed ID: 8396920
[TBL] [Abstract][Full Text] [Related]
5. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles.
Hoffman SW; Moore S; Ellis EF
Stroke; 1997 Apr; 28(4):844-9. PubMed ID: 9099206
[TBL] [Abstract][Full Text] [Related]
6. Selective modulation of the human platelet thromboxane A2/prostaglandin H2 receptor by eicosapentaenoic and docosahexaenoic acids in intact platelets and solubilized platelet membranes.
Parent CA; Lagarde M; Venton DL; Le Breton GC
J Biol Chem; 1992 Apr; 267(10):6541-7. PubMed ID: 1532390
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a thromboxane A2/prostaglandin H2 receptor in guinea pig lung membranes using a radioiodinated thromboxane mimetic.
Saussy DL; Mais DE; Dubé GP; Magee DE; Brune KA; Kurtz WL; Williams CM
Mol Pharmacol; 1991 Jan; 39(1):72-8. PubMed ID: 1824791
[TBL] [Abstract][Full Text] [Related]
8. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic effects of isoprostanes (8-iso-prostaglandin F2alpha and E2) in isolated guinea pig hearts.
Möbert J; Becker BF; Zahler S; Gerlach E
J Cardiovasc Pharmacol; 1997 Jun; 29(6):789-94. PubMed ID: 9234660
[TBL] [Abstract][Full Text] [Related]
10. Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant.
Dorn GW; Burch RM; Kochel PJ; Mais DE; Halushka PV
Biochem Pharmacol; 1987 Jun; 36(12):1913-7. PubMed ID: 2954555
[TBL] [Abstract][Full Text] [Related]
11. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
12. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
Hanasaki K; Arita H
Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
[TBL] [Abstract][Full Text] [Related]
13. Platelet and vascular thromboxane A2/prostaglandin H2 receptors. Evidence for different subclasses in the rat.
Masuda A; Mais DE; Oatis JE; Halushka PV
Biochem Pharmacol; 1991 Jul; 42(3):537-44. PubMed ID: 1830482
[TBL] [Abstract][Full Text] [Related]
14. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M
J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
[TBL] [Abstract][Full Text] [Related]
15. The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human platelets.
Leitinger N; Blazek I; Sinzinger H
Thromb Res; 1997 May; 86(4):337-42. PubMed ID: 9187022
[TBL] [Abstract][Full Text] [Related]
16. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
Naka M; Mais DE; Morinelli TA; Hamanaka N; Oatis JE; Halushka PV
J Pharmacol Exp Ther; 1992 Aug; 262(2):632-7. PubMed ID: 1386885
[TBL] [Abstract][Full Text] [Related]
17. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
18. 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets.
Fonlupt P; Croset M; Lagarde M
Thromb Res; 1991 Jul; 63(2):239-48. PubMed ID: 1837628
[TBL] [Abstract][Full Text] [Related]
19. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
[TBL] [Abstract][Full Text] [Related]
20. Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets.
Dorn GW
J Clin Invest; 1989 Dec; 84(6):1883-91. PubMed ID: 2531760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
